1. Home
  2. LEE vs SKYE Comparison

LEE vs SKYE Comparison

Compare LEE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEE
  • SKYE
  • Stock Information
  • Founded
  • LEE 1890
  • SKYE 2012
  • Country
  • LEE United States
  • SKYE United States
  • Employees
  • LEE N/A
  • SKYE N/A
  • Industry
  • LEE Newspapers/Magazines
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEE Consumer Discretionary
  • SKYE Health Care
  • Exchange
  • LEE Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • LEE 90.6M
  • SKYE 80.7M
  • IPO Year
  • LEE N/A
  • SKYE N/A
  • Fundamental
  • Price
  • LEE $11.45
  • SKYE $3.11
  • Analyst Decision
  • LEE
  • SKYE Buy
  • Analyst Count
  • LEE 0
  • SKYE 6
  • Target Price
  • LEE N/A
  • SKYE $18.67
  • AVG Volume (30 Days)
  • LEE 21.2K
  • SKYE 217.3K
  • Earning Date
  • LEE 02-06-2025
  • SKYE 02-25-2025
  • Dividend Yield
  • LEE N/A
  • SKYE N/A
  • EPS Growth
  • LEE N/A
  • SKYE N/A
  • EPS
  • LEE N/A
  • SKYE N/A
  • Revenue
  • LEE $600,264,000.00
  • SKYE N/A
  • Revenue This Year
  • LEE N/A
  • SKYE N/A
  • Revenue Next Year
  • LEE N/A
  • SKYE N/A
  • P/E Ratio
  • LEE N/A
  • SKYE N/A
  • Revenue Growth
  • LEE N/A
  • SKYE N/A
  • 52 Week Low
  • LEE $7.57
  • SKYE $2.31
  • 52 Week High
  • LEE $19.63
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • LEE 32.24
  • SKYE 51.55
  • Support Level
  • LEE $11.40
  • SKYE $2.60
  • Resistance Level
  • LEE $13.69
  • SKYE $3.54
  • Average True Range (ATR)
  • LEE 0.68
  • SKYE 0.50
  • MACD
  • LEE -0.09
  • SKYE 0.03
  • Stochastic Oscillator
  • LEE 10.27
  • SKYE 30.91

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: